Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) derived from cardiac tissue — one of the most clinically significant peptides in the Khavinson bioregulator series developed at the St. Petersburg Institute of Bioregulation and Gerontology. The heart is among the most metabolically demanding and least regenerative organs in the body, making cardiac-specific epigenetic restoration a compelling target for aging and cardiovascular optimization.

The mechanism that distinguishes Khavinson peptides from conventional cardioprotective drugs is their epigenetic action: Cardiogen's tetrapeptide sequence penetrates cardiomyocyte nuclei and binds specifically to histone-DNA complexes in cardiac chromatin, reactivating the transcription of cardioprotective genes silenced by age-related methylation and histone modification. These genes include those encoding antioxidant enzymes (Mn-SOD, catalase), mitochondrial respiratory chain components critical for cardiomyocyte energy production, heat shock proteins that protect cardiac proteins from oxidative unfolding, and anti-apoptotic factors that maintain cardiomyocyte viability under metabolic stress.

Cardiomyocytes are terminally differentiated cells — the heart has extremely limited regenerative capacity compared to other organ systems. This means that age-related functional decline in cardiomyocytes is particularly consequential: every cell lost to apoptosis or senescence represents a permanent reduction in cardiac reserve. Cardiogen addresses this by enhancing the intrinsic survival machinery of existing cardiomyocytes — reducing apoptotic susceptibility, improving mitochondrial function, and restoring the antioxidant capacity that protects against the chronic oxidative stress inherent to the heart's continuous high-energy metabolic demand.

Animal studies from the Khavinson group demonstrate that Cardiogen treatment in aged rodent models produces measurable improvements in cardiac histology (reduced cardiomyocyte apoptosis, better preserved myofibril architecture), biochemical markers (improved antioxidant enzyme activity, reduced lipid peroxidation products in cardiac tissue), and functional parameters (improved cardiac contractility under stress conditions). The survival data is notable: aged animals receiving periodic Cardiogen courses showed reduced cardiovascular mortality and median lifespan extension — effects the researchers attribute to maintained cardiac functional reserve preventing the cascade of organ failure that commonly terminates aging.

Human clinical application has focused on elderly patients with age-related cardiac dysfunction, individuals recovering from myocardial stress, and preventive protocols in aging populations at elevated cardiovascular risk. Outcomes in published Khavinson group work include improvements in echocardiographic parameters, reduced cardiac biomarker elevation under stress, and subjective improvements in exercise tolerance and cardiac symptomatology. The peptide is not an acute intervention for cardiac emergencies but rather a course-based restoration protocol for maintaining cardiac tissue quality over time.

Standard protocol is 2mg/day for 10 consecutive days, administered subcutaneously or intranasally, with courses repeated 2–4 times annually. The cardiac-specific epigenetic restoration mechanism means effects accumulate with repeated courses — each cycle builds on the transcriptional reactivation established by previous cycles. Combination with SS-31 (mitochondrial-targeted antioxidant with strong cardiomyocyte data) provides mechanistically complementary cardiac protection at the mitochondrial level.